We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · July 05, 2021

Lenvatinib + Pembrolizumab in Treatment-Naive or Previously Treated mRCC

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Lenvatinib Plus Pembrolizumab in Patients With Either Treatment-Naive or Previously Treated Metastatic Renal Cell Carcinoma (Study 111/KEYNOTE-146): A Phase 1b/2 Study
Lancet Oncol 2021 Jul 01;22(7)946-958, CH Lee, AY Shah, D Rasco, A Rao, MH Taylor, C Di Simone, JJ Hsieh, A Pinto, DR Shaffer, R Girones Sarrio, AL Cohn, NJ Vogelzang, MA Bilen, S Gunnestad Ribe, M Goksel, ØK Tennøe, D Richards, RF Sweis, J Courtright, D Heinrich, S Jain, J Wu, EV Schmidt, RF Perini, P Kubiak, CE Okpara, AD Smith, RJ Motzer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading